---
schema_version: "secwatch.filing_event.v1"
accession: "0000950142-22-002314"
form_type: "8-K"
ticker: "VTVT"
cik: "0001641489"
company_name: "vTv Therapeutics Inc."
filed_at: "2022-07-27T23:59:59+00:00"
generated_at: "2026-06-24T08:12:42.593960+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# vTv Therapeutics appoints Paul Sekhri as President and CEO effective August 1, 2022

## Summary
- Paul Sekhri appointed President and CEO effective Aug 1, 2022; succeeds Richard Nelson, who becomes EVP and remains on board.
- Employment terms: $480k base salary, 75% bonus target, 2.2M stock options at $0.79/share (NASDAQ inducement grant).
- Options vest 25% after one year, then quarterly over three years; accelerated vesting on certain performance metrics.
- Severance: 12 months base (18 months post-change of control), COBRA, target bonus; two-year non-compete and non-solicit.
- vTv is preparing Phase 3 trials for TTP399 (type 1 diabetes) with recent $25M G42 investment and Breakthrough Therapy designation.

## SEC filing metadata
- accession: 0000950142-22-002314
- form_type: 8-K
- ticker: VTVT
- cik: 0001641489
- company_name: vTv Therapeutics Inc.
- filed_at: 2022-07-27T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 5.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1641489/000095014222002314/0000950142-22-002314-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1641489/000095014222002314/eh220274048_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950142-22-002314
- JSON: https://secwatch.observer/filing/0000950142-22-002314.json
- Plain text: https://secwatch.observer/filing/0000950142-22-002314.txt

## Key facts
- Executive change
  Richard S. Nelson changed role as Executive Vice President at vTv Therapeutics Inc..
  - Action: ceased to be Interim Chief Executive Officer
  - Role: Executive Vice President
  source text: As of the Effective Date, Richard S. Nelson will cease to be the Interim Chief Executive Officer but will continue to serve as a member of the Board and as an Executive Vice President of the Company.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1641489/000095014222002314/0000950142-22-002314-index.htm
- Executive change
  Paul Sekhri was appointed as President and Chief Executive Officer at vTv Therapeutics Inc..
  - Action: appointed
  - Role: President and Chief Executive Officer
  source text: On July 27, 2022, vTv Therapeutics Inc. (the “Company”) announced that the board of directors of the Company (the “Board”) has appointed Paul Sekhri as President and Chief Executive Officer and as a member of the Board, effective as of August 1, 2022
  evidence_url: https://www.sec.gov/Archives/edgar/data/1641489/000095014222002314/0000950142-22-002314-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.